Rivogenlecleucel not checked

Bellicum Pharmaceuticals · BPX-501 T cells · BPX-501

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
4 active
8 in total
Targets
—
None known yet

What this is

How it works
A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
How it’s given
“Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.”In the company’s words, NCT01744223 on ClinicalTrials.gov
Tested for
Myelodysplastic Syndromes (3 trials), Acute Lymphoblastic Leukemia (2 trials), Lymphoma (2 trials), Acute Myelogenous Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Primary Immune Deficiency Disorder, Osteopetrosis and 7 more
Main trialPhase 1/2
“This study will evaluate patients with blood cell cancers who are going to have an allogeneic (donor) blood stem cell transplant from a partially matched relative. The research study will test whether immune cells, called T cells, which come from the donor relative and are specially grown in the laboratory and then given back to the patient along with the stem cell transplant (T cell addback), can help the immune system recover faster after the transplant. As a safety measure, these T cells have been "programmed" with a "self-destruct switch" so that if, after they have been given to the…”In the company’s words, NCT01744223 on ClinicalTrials.gov
Other names
BPX-501 T cells · BPX-501

Other drugs for Myelodysplastic Syndromes

All 96 drugs for Myelodysplastic Syndromes

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting 9 Oct 2019 Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Phase 1/2Active, not recruiting 11 May 2021 Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Phase 1Active, not recruiting 14 Jan 2020 Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Phase 1Active, not recruiting Sep 2022 Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant
Phase 2/3Terminated 23 Jul 2019 Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
Phase 1/2Terminated 30 Jun 2020 Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Phase 1/2Terminated Jun 2020 Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Phase 1Terminated Sep 2015 Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Rivogenlecleucel

Following is part of Solo: you see every change to Rivogenlecleucel the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in